A Real World Study for the Efficacy and Safety of Large Dose Tanreqing Injection in the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19)

A Real World Study For the Efficacy and Safety of Large Dose Tanreqing Injection in the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19)

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2000002948

Enrollment

Unknown

Registered

2020-02-01

Start date

2020-02-01

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

novel coronavirus pneumonia (COVID-19)

Interventions

Case series:Add 500ml of 5% glucose injection or 0.9% sodium chloride injection into Tanreqing injection, intravenous drip, control the number of drops no more than 60 drops per minute, 1-2 times a da

the dosage is determined by the doctor,but no more than 80ml / day, 40ml / day is recommended.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Confirmed or suspected cases who are comply with the diagnostic criteria for pneumonia caused by novel coronavirus infection in the "Diagnosis and Treatment Program for pneumonia caused by novel coronavirus infection (Trial Version 4)"; 2. Inpatients aged 18-75 years; 3. Obtain the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with severe novel coronavirus pneumonia; 2. Patients with severe basic diseases; 3. Patients who have mental confusion, pregnant or lactating women, who with a history of drug abuse or dependence, who allergic to study medication, who have participated in another clinical trial within 3 months,or who have other conditions not suitable for clinical study.

Design outcomes

Primary

Measure	Time frame
Chest X-ray absorption;Time for body temperature recovery;	—

Secondary

Measure	Time frame
Biochemical Indicators;Routine blood test;Procalcitonin;Liver and renal function;C-reactive protein;Heart enzyme index;Blood gas analysis;	—

Countries

China

Contacts

Public ContactZhongqi Yang, Minyong Wen

The First Afflicated Hospital of Guangzhou University of Chinese Medicine

yang_zhongqi@163.com+86 13688867618

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026